Aesthetic & Injectable Medicine
Aesthetic & Injectable Medicine
Requires Standards 1–7 verified first
4 criteria
| Standard 9.1 NON-NEGOTIABLE · Standard 9: Aesthetic & Injectable Medicine A Licensed Physician Oversees Every Injection, Even If Not the Injector |
ASSESSMENT ASF-AMB-STD9-v3.0 |
| CR N/A | TR FULL | SM FULL | ST FULL |
| 9.1 NON-NEGOTIABLE L1 |
THE STANDARD A Licensed Physician Oversees Every Injection, Even If Not the Injector A licensed physician holds genuine, documented oversight of every injectable procedure performed at this facility, whether or not the physician personally administers each injection — not an arrangement where trained staff inject with no real physician accountability. |
| CLINIC SELF-ASSESSMENT Tick YES, PARTIAL, or NO for each question. |
| 1 | Is there a specific, named licensed physician with documented oversight of injectable procedures here? A specific person and a real, checkable oversight relationship, not an assumed general affiliation. Doc: Physician oversight documentation |
YES | PARTIAL | NO |
| 2 | If a non-physician performs the injection, is the physician's oversight genuine and immediate, not remote or after the fact? Real-time availability and accountability, not a signature reviewed days later. Doc: Oversight protocol document |
YES | PARTIAL | NO |
| 3 | Can the physician describe their actual involvement in a recent case, specifically? A real, specific example, not a general description of the arrangement. Doc: N/A — tested directly |
YES | PARTIAL | NO |
ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.
| WHAT THE ASSESSOR DOES ON SITE no surprises, no hidden checks |
| DOCUMENT Oversight documentation review |
Reviews documentation naming the specific overseeing physician and the nature of their oversight. |
| ASK Physician involvement interview |
Asks the physician to describe their actual, specific involvement in a recent injectable case. |
| OBSERVE Real-time availability check |
Checks whether physician oversight is genuinely immediate during procedures, not remote. |
REFERENCES
- [49] Goodman GJ, Liew S, Callan P, Hart S. Facial aesthetic injections in clinical practice: Pretreatment and posttreatment consensus recommendations to minimise adverse outcomes. Australas J Dermatol. 2020;61(3):217-225 — establishes physician-level clinical oversight, proper patient selection, and technique as core risk-reduction requirements for injectable treatment.
| Standard 9.1 · Standard 9: Aesthetic & Injectable Medicine Guidance & Learning |
GUIDANCE ASF-AMB-STD9-v3.0 |
| WHY THIS STANDARD EXISTS |
Marketing titles and private training certificates don't establish genuine medical oversight, and serious complications from injectables — vascular occlusion, tissue necrosis, vision loss — require real physician-level clinical judgement to prevent and manage, not just technical injection skill.
| WHAT GOOD LOOKS LIKE ✓ A specific, named physician holds genuine, documented oversight. ✓ Oversight is real-time and immediate when a non-physician injects. ✓ The physician can describe specific, real involvement in recent cases. |
WHAT FAILURE LOOKS LIKE ✗ No specific physician is named; oversight is a vague, general claim. ✗ Oversight exists only as after-the-fact paperwork review. ✗ The physician cannot describe any specific recent involvement. |
| MOST COMMON REASONS CLINICS SCORE PARTIAL |
1 A physician is named but is rarely physically present during procedures.
Named oversight without genuine availability doesn't provide real protection during a complication.
2 Oversight is real for complex procedures but looser for routine ones.
Complications can occur even in routine cases; the oversight standard shouldn't depend on perceived complexity.
3 The physician reviews cases in batches at the end of the week.
Delayed review cannot catch or respond to a complication as it's actually happening.
| HOW TO IMPLEMENT IF YOU ARE STARTING FROM ZERO |
Week 1 Confirm and document the specific overseeing physician and their real availability.
Week 2 Establish a real-time oversight protocol for non-physician injectors.
Week 3 Brief all staff on the specific oversight arrangement and escalation process.
Ongoing Review oversight genuineness periodically, including physician availability records.
| FOR SURVEYORS — WHAT IS NOT OBVIOUS |
Ask the physician for a specific, recent case example, not a general description.
Specificity reveals whether oversight is genuine or a formality.
Ask a non-physician injector how they'd reach the physician during a complication, right now.
A confident, specific answer reveals genuine real-time oversight.
| E-LEARNING academy.gmj.ge/amb-std9-1-physician-oversight — 30 min · complete before self-assessment |
| Standard 9.2 NON-NEGOTIABLE · Standard 9: Aesthetic & Injectable Medicine Injectable Products Are Sourced From Verified, Traceable Suppliers |
ASSESSMENT ASF-AMB-STD9-v3.0 |
| CR N/A | TR FULL | SM FULL | ST FULL |
| 9.2 NON-NEGOTIABLE L1 |
THE STANDARD Injectable Products Are Sourced From Verified, Traceable Suppliers Every injectable product used is sourced from a verified, traceable supplier, with batch and lot records retained — not purchased through unverified channels where authenticity cannot be confirmed. |
| CLINIC SELF-ASSESSMENT Tick YES, PARTIAL, or NO for each question. |
| 1 | Is every injectable product sourced from a verified, traceable supplier, not an unverified or informal channel? A checkable, legitimate supply chain, not just a lower price. Doc: Supplier verification record |
YES | PARTIAL | NO |
| 2 | Are batch and lot numbers retained for every product used, linked to the patient record? Traceability that would allow a recall or adverse event investigation to actually work. Doc: Batch and lot tracking record |
YES | PARTIAL | NO |
| 3 | Can staff describe how they'd recognise a counterfeit or suspicious product? Genuine awareness, not an assumption that sourcing alone guarantees authenticity. Doc: N/A — tested directly |
YES | PARTIAL | NO |
ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.
| WHAT THE ASSESSOR DOES ON SITE no surprises, no hidden checks |
| DOCUMENT Supplier verification review |
Reviews documentation confirming products are sourced from verified suppliers. |
| DOCUMENT Batch tracking review |
Reviews batch and lot records for completeness and linkage to patient records. |
| ASK Counterfeit awareness interview |
Asks staff how they would recognise a suspicious or counterfeit product. |
REFERENCES
- [50] Counterfeit injectable products, including unapproved botulinum toxin and dermal filler formulations, are a recognised and actively monitored risk in aesthetic medicine, with regulatory bodies issuing specific warnings to both practitioners and patients about verifying product source and authenticity before use.
| Standard 9.2 · Standard 9: Aesthetic & Injectable Medicine Guidance & Learning |
GUIDANCE ASF-AMB-STD9-v3.0 |
| WHY THIS STANDARD EXISTS |
Counterfeit botulinum toxin and dermal filler products are a real, documented risk — unverified sourcing means a facility cannot actually confirm what's being injected into a patient, regardless of how skilled the injector is.
| WHAT GOOD LOOKS LIKE ✓ All products are sourced from verified, traceable suppliers. ✓ Batch and lot records are complete and linked to patient records. ✓ Staff describe genuine awareness of counterfeit product risk. |
WHAT FAILURE LOOKS LIKE ✗ Sourcing channels cannot be verified or are informal. ✗ Batch and lot records are incomplete or not retained. ✗ Staff show no awareness of counterfeit product risk. |
| MOST COMMON REASONS CLINICS SCORE PARTIAL |
1 Primary products are verified but occasional supplementary products are not.
Every injectable product carries the same real authenticity risk, not only the primary ones.
2 Batch numbers are recorded but not consistently linked to the specific patient treated.
Traceability requires the link to the patient, not just the product record alone.
3 Verification happened once at the start of a supplier relationship but isn't ongoing.
A supplier's legitimacy isn't guaranteed to remain constant without periodic reconfirmation.
| HOW TO IMPLEMENT IF YOU ARE STARTING FROM ZERO |
Week 1 Review current suppliers for all injectable products against verification standards.
Week 2 Establish batch and lot tracking linked to patient records.
Week 3 Train staff on recognising counterfeit or suspicious product indicators.
Ongoing Periodically reconfirm supplier legitimacy.
| FOR SURVEYORS — WHAT IS NOT OBVIOUS |
Ask to see the actual supplier verification and batch records, not a general assurance.
Documented, specific records are the only real evidence of genuine traceability.
Ask staff directly what would make them suspicious of a product's authenticity.
Genuine awareness reveals itself in specific, real answers, not a memorized policy line.
| E-LEARNING academy.gmj.ge/amb-std9-2-product-sourcing — 30 min · complete before self-assessment |
| Standard 9.3 NON-NEGOTIABLE · Standard 9: Aesthetic & Injectable Medicine Vascular Occlusion Is Recognised and Treated Within Minutes, Not Hours |
ASSESSMENT ASF-AMB-STD9-v3.0 |
| CR N/A | TR FULL | SM FULL | ST FULL |
| 9.3 NON-NEGOTIABLE L1 |
THE STANDARD Vascular Occlusion Is Recognised and Treated Within Minutes, Not Hours Staff performing filler injections are specifically trained to recognise the signs of vascular occlusion immediately, with hyaluronidase or the appropriate emergency treatment genuinely available on-site — not requiring the patient to be sent elsewhere before treatment can begin. |
| CLINIC SELF-ASSESSMENT Tick YES, PARTIAL, or NO for each question. |
| 1 | Are staff specifically trained to recognise the early signs of vascular occlusion during and immediately after injection? Specific, trained recognition, not general awareness that complications exist. Doc: Vascular occlusion recognition training record |
YES | PARTIAL | NO |
| 2 | Is hyaluronidase, or the appropriate treatment for the products used, genuinely available on-site, not requiring off-site sourcing? Immediately available, not something ordered after a complication is recognised. Doc: On-site emergency treatment stock record |
YES | PARTIAL | NO |
| 3 | Is there a defined, immediate escalation process if a suspected occlusion doesn't respond to initial treatment? A specific next step, not uncertainty about what happens if first-line treatment isn't enough. Doc: Escalation protocol |
YES | PARTIAL | NO |
ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.
| WHAT THE ASSESSOR DOES ON SITE no surprises, no hidden checks |
| DOCUMENT Recognition training review |
Reviews training records for specific vascular occlusion recognition, not general complication awareness. |
| OBSERVE On-site treatment stock check |
Physically confirms hyaluronidase or appropriate treatment is genuinely on-site and in date. |
| ASK Escalation protocol interview |
Asks staff what happens if a suspected occlusion doesn't respond to initial treatment. |
REFERENCES
- [51] Goodman GJ, Liew S, Callan P, Hart S. Facial aesthetic injections in clinical practice: Pretreatment and posttreatment consensus recommendations to minimise adverse outcomes. Australas J Dermatol. 2020;61(3):217-225 — identifies prompt recognition and treatment of vascular occlusion, including high-dose hyaluronidase availability, as critical to preventing permanent tissue damage.
| Standard 9.3 · Standard 9: Aesthetic & Injectable Medicine Guidance & Learning |
GUIDANCE ASF-AMB-STD9-v3.0 |
| WHY THIS STANDARD EXISTS |
Vascular occlusion is the most serious acute complication of filler injection, and the window for effective treatment is measured in hours, not days — delayed recognition or treatment can result in permanent tissue necrosis or vision loss that timely intervention could have prevented.
| WHAT GOOD LOOKS LIKE ✓ Staff are specifically trained to recognise early signs of vascular occlusion. ✓ Appropriate emergency treatment is genuinely on-site and in date. ✓ A specific, known escalation process exists beyond initial treatment. |
WHAT FAILURE LOOKS LIKE ✗ Training covers general complications without specific occlusion recognition. ✗ Emergency treatment isn't on-site or is expired. ✗ Staff are uncertain what happens if initial treatment isn't sufficient. |
| MOST COMMON REASONS CLINICS SCORE PARTIAL |
1 Training happened once at hiring but hasn't been refreshed since.
Rapid recognition under real pressure benefits from periodic reinforcement, not a single training session.
2 Hyaluronidase is stocked but its expiry date wasn't recently checked.
Expired emergency treatment provides no real protection when actually needed.
3 Recognition training is strong for the injector but not for supporting staff who might notice symptoms first.
A patient may report symptoms to any staff member present, not only the injector.
| HOW TO IMPLEMENT IF YOU ARE STARTING FROM ZERO |
Week 1 Review current vascular occlusion recognition training for specificity and recency.
Week 2 Confirm on-site emergency treatment stock and expiry dates.
Week 3 Establish and brief staff on a specific escalation protocol.
Ongoing Refresh recognition training periodically, including for supporting staff.
| FOR SURVEYORS — WHAT IS NOT OBVIOUS |
Ask to see the actual hyaluronidase stock and check its expiry date directly.
Physical verification is the only real evidence of genuine on-site availability.
Ask a supporting staff member, not just the injector, how they'd recognise a complication.
This reveals whether recognition training genuinely reaches everyone present, not just the injector.
| E-LEARNING academy.gmj.ge/amb-std9-3-vascular-occlusion — 30 min · complete before self-assessment |
| Standard 9.4 CORE · Standard 9: Aesthetic & Injectable Medicine Patients Are Screened for Genuine Medical Suitability Before Treatment |
ASSESSMENT ASF-AMB-STD9-v3.0 |
| CR N/A | TR FULL | SM FULL | ST FULL |
| 9.4 CORE L1 |
THE STANDARD Patients Are Screened for Genuine Medical Suitability Before Treatment Every patient undergoes a genuine medical suitability screening before treatment — relevant medical history, medications, prior reactions — not a booking process that moves directly from consultation to injection with no real screening step. |
| CLINIC SELF-ASSESSMENT Tick YES, PARTIAL, or NO for each question. |
| 1 | Does every patient undergo a genuine medical suitability screening before treatment, not just a booking conversation? A real, structured screening step, not an informal chat covering only what the patient happens to mention. Doc: Screening documentation |
YES | PARTIAL | NO |
| 2 | Does screening specifically cover relevant medications, prior reactions, and medical conditions that change risk? Specific, relevant questions, not a generic intake form. Doc: Screening content review |
YES | PARTIAL | NO |
| 3 | Where screening identifies a relevant risk factor, does this genuinely change the treatment decision? Screening that never changes an outcome isn't providing real protection. Doc: N/A — tested directly |
YES | PARTIAL | NO |
ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Requires improvement plan.
| WHAT THE ASSESSOR DOES ON SITE no surprises, no hidden checks |
| DOCUMENT Screening documentation review |
Reviews a sample of patient records for genuine, structured screening before treatment. |
| DOCUMENT Screening content review |
Reviews the screening tool for coverage of medications, prior reactions, and relevant conditions. |
| ASK Risk-factor response interview |
Asks staff for a real example where screening identified a risk factor that changed the treatment plan. |
REFERENCES
- [52] Goodman GJ, Liew S, Callan P, Hart S. Facial aesthetic injections in clinical practice: Pretreatment and posttreatment consensus recommendations to minimise adverse outcomes. Australas J Dermatol. 2020;61(3):217-225 — identifies careful pretreatment patient selection as an essential risk-reduction step, distinct from general consultation.
| Standard 9.4 · Standard 9: Aesthetic & Injectable Medicine Guidance & Learning |
GUIDANCE ASF-AMB-STD9-v3.0 |
| WHY THIS STANDARD EXISTS |
Certain medical conditions, medications, and prior reactions genuinely change the risk profile of an injectable procedure, and a booking process that skips real screening treats every patient as equally low-risk, which they are not.
| WHAT GOOD LOOKS LIKE ✓ Every patient undergoes genuine, structured screening before treatment. ✓ Screening specifically covers medications, prior reactions, and relevant conditions. ✓ A real example exists of screening changing a treatment decision. |
WHAT FAILURE LOOKS LIKE ✗ Screening is informal or skipped, moving directly to treatment. ✗ Screening content is generic and doesn't probe relevant risk factors. ✗ No example exists of screening ever changing a treatment decision. |
| MOST COMMON REASONS CLINICS SCORE PARTIAL |
1 Screening happens for new patients but isn't repeated for returning ones.
A patient's medical situation can change meaningfully between visits.
2 Screening covers medications but not prior reaction history specifically.
Prior reaction history is one of the strongest predictors of future risk.
3 Screening identifies a risk factor but the decision to proceed anyway isn't documented with reasoning.
Undocumented reasoning makes it impossible to confirm the decision was genuinely considered.
| HOW TO IMPLEMENT IF YOU ARE STARTING FROM ZERO |
Week 1 Review current screening practice for genuine structure and content.
Week 2 Build or strengthen a screening tool covering medications, prior reactions, and relevant conditions.
Week 3 Establish screening for returning patients, not only new ones.
Ongoing Document reasoning whenever a screening-identified risk factor doesn't change the treatment decision.
| FOR SURVEYORS — WHAT IS NOT OBVIOUS |
Ask for a real example where screening changed what was done for a patient.
A real example reveals whether screening is genuine practice or a formality.
Check whether screening is repeated for returning patients.
This is a common, specific gap — screening often concentrates only on new-patient intake.
| E-LEARNING academy.gmj.ge/amb-std9-4-patient-screening — 30 min · complete before self-assessment |
Ambulatory Clinic Standards — overviewFacility Classification — Which Type of Facility Are You?Standard 1 — Access & ArrivalStandard 2 — Reception & InformationStandard 3 — Environment & Shared SpacesStandard 4 — Care & TreatmentStandard 5 — Safety & Emergency PreparednessStandard 6 — Aftercare & Follow-upStandard 7 — Governance & ManagementStandard 8 — Dental PracticeStandard 9 — Aesthetic & Injectable MedicineStandard 10 — Longevity & IV TherapyStandard 11 — Oncology & Infusion TherapyStandard 12 — Dialysis & Renal Replacement TherapyStandard 13 — Fertility & IVFStandard 14 — Cardiology & Cardiac CatheterizationStandard 15 — Ophthalmology & Day SurgeryStandard 16 — Diagnostic ImagingStandard 17 — DermatologyStandard 18 — Allergy & ImmunotherapyStandard 19 — Plastic & Cosmetic SurgeryStandard 20 — Psychiatry & Mental HealthStandard 21 — Narcology & Addiction TreatmentStandard 22 — Gastroenterology & EndoscopyStandard 23 — Pediatric Ambulatory CareStandard 24 — Medical TourismStandard 25 — Refugee & Migrant HealthReferences & Index
STANDARD 9Aesthetic & Injectable Medicine9.1 A Licensed Physician Oversees Every Injection, Even If Not the Injector9.2 Injectable Products Are Sourced From Verified, Traceable Suppliers9.3 Vascular Occlusion Is Recognised and Treated Within Minutes, Not Hours9.4 Patients Are Screened for Genuine Medical Suitability Before Treatment
Test your facility against this standard
Open self-assessment — no login, no fee.
Print to share.
